基本情况:

民族：汉  

出生年月：1992年8月

常用邮箱：1968692884@qq.com

教育及工作经历：

2019.09-至今         南京大学                药学          博士

2016.09-2019.06       大连医科大学            药理学        硕士

2011.09-2016.06       大连医科大学          临床药学        学士

发表论文情况:

1. Jiao Qu, Zhihui Zhang, Panpan Zhang, Cheng Zheng, Wencheng Zhou, Wenhui Cui, Liang Xu and Jian Gao. Downregulation of HMGB1 is required for the protective role of Nrf2 in EMT mediated PF. J Cell Physiol. 2019 Jun;234(6):8862-8872.

2. Zhihui Zhang#, Jiao Qu#, Cheng Zheng, Panpan Zhang, Wencheng Zhou, Wenhui Cui, Xiaoting Mo, Liucheng Li, Liang Xu and Jian Gao. Activating Nrf2-dependent antioxidant pathway suppresses Numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis. Cell Death Dis. 2018 Jan 23;9(2):83. (co-first author) 

3. Jiao Qu, Li Yue, Hongwei Yao, Jian Gao. Perspectives on Wnt signal pathway in the pathogenesis and therapeutics in chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2019 Jun;369(3):473-480.

4.  Qianqian Liu#, Jiao Qu#, Mingxia Zhao, Qiang Xu, Yang Sun. Targeting SHP2 as a promising strategy for cancer immunotherapy. Pharmacol Res. 2020 Feb;152:104595. (co-first author) 

5. Liucheng Liu, Zhihui Zhang, Wencheng Zhou, Jie Cheng, Jiao Qu*, Liandi Kan*. Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2020.110641

(Co corresponding author)

6. Liucheng Liu, Yongyue Han, Zhihui Zhang, Wencheng Zhou, Jie Cheng, Jiao Qu*, Liandi Kan*. Chronic obstructive pulmonary disease treatment and pharmacist-led medication management. Drug Des Devel Ther,2021 Jan 12;15:111-124. (Co corresponding author)